UPDATE: On July 28, Genentech announced that the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter COVACTA study did not meet its primary endpoint of showing improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. The study also failed to meet key secondary endpoints, including reduced patient mortality.
UPDATE: On September 17, Genentech announced that the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter EMPACTA study met its primary endpoint showing that the cumulative proportion of hospitalized COVID-19 pneumonia patients who progressed to mechanical ventilation or death by day 28 was less in Actemra-treated patients compared to placebo. The study did not meet key secondary endpoints, including improvement in patient mortality. No new safety signals for Actemra were identified.

The use of ACTEMRA in COVID-19 pneumonia patients has not been approved by the FDA.

Genentech Medical Affairs is providing healthcare providers with up-to-date information on ACTEMRA to enable physicians to make informed individual patient treatment decisions.

Genentech Medical Responses to ACTEMRA in COVID-19 Inquiries

Potential Role of IL-6 and Roche Trials in COVID-19 Pneumonia

For additional online medical resources, to submit a question, or to virtually connect with a Genentech Medical Science Liaison (MSL), please view